Developing Pyrrole‐Derived Antimycobacterial Agents: a Rational Lead Optimization Approach

Tuberculosis (TB) represents a never‐ending challenge toward which research efforts are needed. Drug resistance is the key problem that scientists in the field need to fight. The development of new drugs endowed with novel modes of action against different biological targets is of extreme importance; these new agents should also exhibit lower toxicity compared with the anti‐TB drugs currently available. Furthermore, new drugs should be inexpensive since most of the TB‐infected population lives in developing nations. In the last few years, numerous researchers have focused their attention on TB, leading to the discovery of some interesting compounds. Among these, the pyrrole‐derived compounds we developed can be considered very promising antimycobacterial agents. Aided by molecular modeling studies, we synthesized numerous compounds characterized by the same 1,5‐diarylpyrrole scaffold and elucidated very interesting antitubercular/antimycobacterial properties. Some compounds identified are extremely promising and represent a step towards the design of novel lead structures in the fight against TB. Our efforts to this end are reviewed here.

[1]  Fabrizio Manetti,et al.  Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity. , 2006, Journal of medicinal chemistry.

[2]  Vadim Makarov,et al.  Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. , 2010, Journal of the American Chemical Society.

[3]  Fabrizio Manetti,et al.  1,5-Diphenylpyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings. , 2008, Journal of medicinal chemistry.

[4]  Marianne Terrot,et al.  Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. , 2003, Journal of combinatorial chemistry.

[5]  Mehran Hosseini,et al.  Global incidence of multidrug-resistant tuberculosis. , 2006, The Journal of infectious diseases.

[6]  M. Spigelman,et al.  New tuberculosis therapeutics: a growing pipeline. , 2007, The Journal of infectious diseases.

[7]  M. Cynamon,et al.  Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. , 1996, Journal of medicinal chemistry.

[8]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[9]  M. Eller,et al.  Single and multiple dose pharmacokinetics of rifapentine in man: part II. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  Rossella Fioravanti,et al.  Bactericidal Activities of the Pyrrole Derivative BM212 against Multidrug-Resistant and Intramacrophagic Mycobacterium tuberculosis Strains , 1998, Antimicrobial Agents and Chemotherapy.

[11]  Fabrizio Manetti,et al.  Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin. , 2010, Bioorganic & medicinal chemistry.

[12]  Ping Chen,et al.  Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. , 2006, The Journal of antimicrobial chemotherapy.

[13]  M. Matsumoto,et al.  OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.

[14]  R. Pompei,et al.  New pyrrole derivatives as antimycobacterial agents analogs of BM212. , 1999, Bioorganic & medicinal chemistry letters.

[15]  M. Botta,et al.  Building a pharmacophore model for a novel class of antitubercular compounds. , 2000, Farmaco.

[16]  Fabrizio Manetti,et al.  1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: design, synthesis, and microbiological evaluation. , 2009, European journal of medicinal chemistry.

[17]  Pilho Kim,et al.  PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.

[18]  H. McIlleron,et al.  Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  D. Mitchison,et al.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  Charles M Heilig,et al.  Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. , 2009, American journal of respiratory and critical care medicine.

[21]  M. Cynamon,et al.  Activities of Several Novel Oxazolidinones againstMycobacterium tuberculosis in a Murine Model , 1999, Antimicrobial Agents and Chemotherapy.

[22]  I. Smith,et al.  XDR tuberculosis--implications for global public health. , 2007, The New England journal of medicine.

[23]  Thomas R Frieden,et al.  The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century. , 2002, Infectious disease clinics of North America.

[24]  Dirk Bald,et al.  Diarylquinolines target subunit c of mycobacterial ATP synthase. , 2007, Nature chemical biology.

[25]  William R Bishai,et al.  Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial , 2009, The Lancet.

[26]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[27]  Mariangela Biava,et al.  BM 212 and its derivatives as a new class of antimycobacterial active agents. , 2002, Current medicinal chemistry.

[28]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[29]  L. Heifets,et al.  Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. , 1990, The American review of respiratory disease.

[30]  C. Nacy,et al.  Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs , 2007, Antimicrobial Agents and Chemotherapy.

[31]  R. O'brien,et al.  The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. , 2001, American journal of respiratory and critical care medicine.